Today: 9 June 2026
Browse Category

NASDAQ:TVTX 24 December 2025 - 13 January 2026

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals shares fell 10.6% after the FDA extended its review of partner Travere’s Filspari label expansion, resetting the decision deadline to April 13. Travere shares dropped 19%. The FDA classified the latest filing as a “major amendment” but did not request new safety or manufacturing data. The broader biotech sector was little changed.
13 January 2026
···
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April

Travere Therapeutics shares fell 19% Tuesday after the FDA extended its review of Filspari for broader use in kidney disease, pushing the decision deadline to April 13. The stock hit an intraday low of $22.35 before recovering. Travere forecast $127 million in Q4 U.S. net product sales and ended 2025 with $323 million in cash and equivalents. Analyst Joseph Schwartz warned a formal rejection from the FDA remains possible.
13 January 2026
··
Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics shares dropped 5.3% to $36.09 Tuesday ahead of the FDA’s Jan. 13 decision on expanding kidney drug Filspari’s label. Options trading surged, with heavy put activity at the $35 strike. Chief Medical Officer Jula Inrig disclosed a planned sale of 15,000 shares to cover taxes. CEO Eric Dube will present at the J.P. Morgan Healthcare Conference on Jan. 12.
6 January 2026
··
Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Why Travere Therapeutics (TVTX) stock is down today as insider sales hit the tape ahead of a key FDA date

Travere Therapeutics shares fell 3.8% to $37.39 Tuesday afternoon, outpacing declines in biotech ETFs. SEC filings showed Chief Medical Officer Jula Inrig and Chief Commercial Officer Pieter Heerma sold shares on Dec. 24 under pre-arranged 10b5-1 plans. The moves come weeks before a key FDA decision on Filspari for FSGS, set for Jan. 13, 2026. Trading volume reached about 893,000 shares.
30 December 2025
Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

Travere Therapeutics (TVTX) Stock Watch: Pre‑Market Focus on the Jan. 13 FDA Decision After a 14% Rally

Travere Therapeutics shares closed at $40.28 on Dec. 24, up 13.9% after bullish analyst commentary and anticipation of an FDA decision on FILSPARI for FSGS by Jan. 13, 2026. Early pre-market trading Friday showed TVTX around $40.6. The FDA dropped plans for an advisory committee meeting, which some investors see as a positive sign. Trading volume remains light due to the holiday.
26 December 2025
Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets

Travere Therapeutics shares jumped about 15% to over $40 in early trading on Dec. 24, 2025, hitting new highs during a holiday-shortened session. The surge followed investor anticipation of an FDA decision on FILSPARI for FSGS, expected by Jan. 13, 2026. No company news was released that day. The FDA previously waived an advisory committee review for the application.
24 December 2025
·

Stock Market Today

  • Wise Group (WSE) Gains Analyst Attention with Nasdaq Listing and New Multi-Currency Feature
    June 9, 2026, 1:06 PM EDT. Wise Group plc (NASDAQ:WSE), a global payments firm, began trading on Nasdaq on May 11 while keeping its London Stock Exchange listing. BNP Paribas initiated coverage with an Outperform rating and a 1,240 GBp price target. The company recently launched a multi-currency Interest feature in Canada, allowing customers to earn interest on EUR, GBP, CAD, and USD balances without minimums or penalties. Wise offers cross-border payment solutions to banks and consumers. Analysts see potential but suggest some AI stocks present higher upside and lower risk. Wise's Nasdaq debut and product innovations mark key growth steps.

Latest articles

United Natural Foods Shares Fall After Revenue Miss

United Natural Foods Shares Fall After Revenue Miss

9 June 2026
United Natural Foods plunged 12.4% to $45.25 after quarterly revenue missed estimates, falling 4.2% to $7.72 billion versus the $7.80 billion consensus, with full-year guidance also slightly below Wall Street expectations, despite matching adjusted EPS and improved profit and debt metrics.
BlackBerry Shares Stall After QNX Push

BlackBerry Shares Slip Ahead of Results — What’s Moving BB Today

9 June 2026
BlackBerry’s U.S. shares plunged 8.5% to $8.50 as investors braced for the June 25 earnings report, with focus on whether the company can meet its bullish Q1 revenue forecast of $132–$140 million, well above analysts’ estimates, after QNX’s 20% revenue jump and $950 million royalty backlog last quarter.
Chip Selloff Trips Up Wall Street’s AI Rally

Chip Selloff Trips Up Wall Street’s AI Rally

9 June 2026
Nasdaq and S&P 500 tumbled midday, erasing early chip-stock gains as tech shares slid; Philadelphia Semiconductor Index dropped 2% after jumping 3%, with Broadcom, Micron, and Nvidia under pressure. Investors await key inflation data Wednesday and SpaceX’s massive IPO, both seen as catalysts for further volatility amid concerns that high valuations in AI and tech could face profit-taking if rate fears persist.
Nintendo and Sanrio Stocks Get New AI Boost

Nintendo and Sanrio Stocks Get New AI Boost

9 June 2026
Nintendo hikes Switch 2 prices in Japan and the US, citing higher memory costs and tariffs expected to add 100 billion yen to annual expenses; investors now question whether Japan’s top entertainment brands like Nintendo and Sanrio can maintain valuations as AI-driven capital shifts toward chips and automation, pressuring stock selection even as the Nikkei rebounds 2.17% after Monday’s sharp drop.
Costco Drops Kirkland Prices While Prepping New Florida Warehouse

Costco Drops Kirkland Prices While Prepping New Florida Warehouse

9 June 2026
Costco slashed prices on select Kirkland Signature products by up to $10 as part of its strategy to boost membership renewals, but shares barely moved, last at $973.50, down $1.25, after Q3 net sales rose 11.6% to $69.15 billion and net income hit $2.19 billion; management emphasized the cuts are strategic, not a chainwide rollback, amid slowing paid membership growth and ongoing competitive pressure.
Go toTop